Hospital groups sue HHS seeking 340B price transparency

September 11, 2018: The AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. Required by Congress in 2010, HHS has delayed the rule’s effective date five times. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers.


Complaint

Motion for Summary Judgment

Memorandum in Support of Motion

Related Resources

Special Bulletin
The Centers for Medicare & Medicaid Services (CMS) today released the calendar year (CY) 2021 outpatient prospective payment system (OPPS)/ambulatory…
Letter/Comment
Public
AHA expresses concern regarding recent action taken by three major drug manufacturers – Eli Lilly and Co., Merck and Sanofi – to limit the distribution of…
Webinar Recordings
Member
A panel of 4 experts discussed federal policy emerging from Congress and the Administration under COVID-19 focusing on rural health priorities and took…
Letter/Comment
Public
Dear Secretary Azar: On behalf of our nearly 2,000 340B member hospitals, the American Hospital Association (AHA) urges the Department of Health and Human…
Letter/Comment
Public
The AHA submitted its comments to the Office of Management and Budget regarding the Centers for Medicare & Medicaid Services (CMS) plans to collect pricing…
Guides/Reports
Member
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec lacus justo, scelerisque ut orci vitae, venenatis dignissim sapien. In vitae enim quis purus…